Aclaris Therapeutics Inc. (ACRS) Stock Forecast & Analysis

Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Aclaris Therapeutics Inc. (ACRS:NASDAQ), powered by AI.

Current Price
$4.34
Sector
Healthcare
What is the Aclaris Therapeutics Inc. stock price forecast?

Aclaris Therapeutics Inc. is currently trading at $4.34. View real-time AI analysis on Alpha Lenz.

What is Aclaris Therapeutics Inc. insider trading activity?

View the latest insider trading data for Aclaris Therapeutics Inc. on Alpha Lenz.

What is Aclaris Therapeutics Inc.'s P/E ratio?

View Aclaris Therapeutics Inc.'s valuation metrics on Alpha Lenz.

Aclaris Therapeutics Inc.

NASDAQ · ACRS
$4.34-0.02(-0.46%)Pre-marketNASDAQ regular session 09:30–16:00 ET
Ask about Aclaris Therapeutics Inc.'s future dividend policy...
Alpha Chat Insight

Aclaris Therapeutics Inc.'s ROE is -50.2%. Explore profitability and growth together.

Ask for details

Company Overview

Aclaris Therapeutics Inc. is a biopharmaceutical company focused on developing innovative therapies to address unmet needs in dermatology, immunology, and neurology. The company's primary objective is to discover and develop novel drug candidates that can be game-changers in treating conditions with limited treatment options. Notable for its pipeline of compounds targeting immuno-inflammatory regulatory mechanisms, Aclaris aims to bring new solutions to chronic skin conditions like psoriasis and vitiligo, as well as broader autoimmune disorders. The company's expertise in utilizing scientific advances complements its dedication to delivering effective treatments through rigorous clinical studies. Aclaris plays a significant role in the pharmaceutical landscape, contributing towards expanding therapeutic options in specialized medical fields, thereby potentially improving quality of life for patients worldwide. Its innovative approach and commitment to furthering medical research solidify its position as a pioneering entity within the biotech industry.

CEODr. Neal S. Walker D.O., M.D.
SectorHealthcare
IndustryBiotechnology
Employees61

Company Statistics

FY 2025

Profile

N/AMarket Cap
$7.83MRevenue
0.00Shares Out
61Employees

Margins

6.93%Gross
-862.59%EBITDA
-897.78%Operating
-829.58%Pre-Tax
-829.58%Net

Valuation

N/AP/E
N/AP/B
N/AEV/Sales
N/AEV/EBITDA
N/AP/FCF

Growth (CAGR)

-35.93%Rev 3Yr
3.84%Rev 5Yr
N/AOp Inc 3Yr
N/AOp Inc 5Yr
N/ANet Inc 3Yr
N/ANet Inc 5Yr

Returns

-34.10%ROA
-50.20%ROE
-36.90%ROIC

Financial Health

$19.96MCash & Cash Equivalents
$37.42MNet Debt
55.66%Debt/Equity
N/AInterest Cov

Frequently Asked Questions

Aclaris Therapeutics Inc. (ticker: ACRS) is a company listed on NASDAQ in the Healthcare sector (Biotechnology). It has approximately 61 employees.

The current price is $4.34 with a P/E ratio of -x and P/B of -x.

ROE is -50.20% and operating margin is -897.78%. Annual revenue is $8M.

Alpha Lenz
Singapore
Treasurer Pte Ltd | License: 202346277E
9 Straits View Marina One West Tower #05-07 Singapore 018937
contact@treasurer.co.kr
©2026 Treasurer Pte Ltd. All rights reserved.
Aclaris Therapeutics Inc. (ACRS) Stock Forecast 2026 $4.34 — Price, Financials & Analyst Targets | Alpha Lenz